Wall Street brokerages predict that SQZ Biotechnologies (NYSE:SQZ – Get Rating) will post sales of $4.17 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for SQZ Biotechnologies’ earnings, with the lowest sales estimate coming in at $3.00 million and the highest estimate coming in at $4.92 million. SQZ Biotechnologies reported sales of $4.54 million in the same quarter last year, which indicates a negative year over year growth rate of 8.1%. The firm is scheduled to announce its next earnings results on Monday, January 1st.
On average, analysts expect that SQZ Biotechnologies will report full year sales of $30.56 million for the current year, with estimates ranging from $12.87 million to $57.61 million. For the next financial year, analysts anticipate that the business will post sales of $33.30 million, with estimates ranging from $21.00 million to $40.00 million. Zacks’ sales averages are an average based on a survey of analysts that follow SQZ Biotechnologies.
SQZ Biotechnologies (NYSE:SQZ – Get Rating) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.06). SQZ Biotechnologies had a negative net margin of 303.43% and a negative return on equity of 57.79%.
Several institutional investors have recently made changes to their positions in the stock. Citigroup Inc. raised its stake in shares of SQZ Biotechnologies by 139.6% in the third quarter. Citigroup Inc. now owns 2,595 shares of the company’s stock worth $37,000 after buying an additional 1,512 shares during the period. Royal Bank of Canada increased its stake in SQZ Biotechnologies by 96.2% in the 3rd quarter. Royal Bank of Canada now owns 3,059 shares of the company’s stock worth $44,000 after acquiring an additional 1,500 shares during the last quarter. UBS Group AG boosted its holdings in shares of SQZ Biotechnologies by 85.8% in the 3rd quarter. UBS Group AG now owns 7,000 shares of the company’s stock worth $101,000 after purchasing an additional 3,233 shares during the period. Metropolitan Life Insurance Co NY purchased a new position in SQZ Biotechnologies during the 3rd quarter valued at $104,000. Finally, Bangor Savings Bank purchased a new position in SQZ Biotechnologies during the 4th quarter valued at $99,000. Institutional investors own 66.56% of the company’s stock.
About SQZ Biotechnologies (Get Rating)
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.
- Get a free copy of the StockNews.com research report on SQZ Biotechnologies (SQZ)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.